(Q35077217)

6 August 2017

1 reference

title

Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome (English)

1 reference

6 August 2017

1 reference

1 reference

James R Sowers

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

91

1 reference

6 August 2017

issue

4A

1 reference

6 August 2017

page(s)

14B-22B

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Diabetes trends in the U.S.: 1990-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Diabetes, hypertension, and cardiovascular disease: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Serum cholesterol in young men and subsequent cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Isoprenoids as mediators of the biological effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Non-lipid-related effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Structural mechanism for statin inhibition of HMG-CoA reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Rho GTPases and signaling networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Insulin-mediated vasodilation: impairment with increased blood pressure and body mass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Insulin-mediated venodilation is impaired in patients with high cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Type II diabetes abrogates sex differences in endothelial function in premenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Endothelial vasodilation effects of statins in type 2 diabetic patients: response to van Venrooij et al

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Rho GTPases and the actin cytoskeleton

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Hypertension, angiotensin II, and oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Mobilization of endothelial progenitor cells in patients with acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903269-1

10.1016/S0002-9149(02)03269-1

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference